Turn Therapeutics (TTRX)
Develops GX-03 for skin disease while licensing medical-device products.
Something off on this page? Send us feedback.
Develops the topical GX-03 candidate for atopic dermatitis and a subsequent onychomycosis program, supported by the PermaFusion drug-performance platform. The business combines internal drug development with third-party licensing or sales of a legacy FDA-cleared device portfolio.
GX-03 is the central program in a dermatology-focused clinical-development portfolio. The topical candidate is in an adaptive Phase 2 study for atopic dermatitis, while the company describes onychomycosis as a subsequent drug-development program. PermaFusion, a platform intended to enhance drug performance, underpins this work. Earlier GX-03 wound-care applications and other FDA-cleared devices form a separate device legacy.
Operations pair third-party licensing or sale of medical-device products with internal drug development. Manufacturing, packaging, and sterilization are performed in the United States. Progress depends on clinical-trial results, regulatory clearances or approvals, commercial partners, manufacturing, intellectual-property protection, and access to capital.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.3M · Total debt $6.1M · Total assets $17.0M · Shareholders' equity $686.9K
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$5.8M
No dividends on record.
| Institutions20 holders · as of Mar 31, 2026 | 1.55% | 462.3K shares | |
| Otherremainder | 98.45% | 29.33M shares |
29.79M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
DDFG, IncInstitution | 0.24% | 70,534 | 13Fas of Mar 31, 2026 |
Millennium Management LLCInstitution | 0.23% | 69,757 | 13Fas of Mar 31, 2026 |
Wellington Shields & Co., LLCInstitution | 0.22% | 65,732 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 0.17% | 49,450 | 13Fas of Mar 31, 2026 |
Tamar Securities, LLCInstitution | 0.10% | 30,000 | 13Fas of Mar 31, 2026 |
| See all 20 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Incyte
Topical JAK option for mild-to-moderate atopic dermatitis
- Arcutis Biotherapeutics
Topical PDE4 option for mild-to-moderate atopic dermatitis
- Organon
Once-daily steroid-free topical for atopic dermatitis
- Sanofi (ADR)
IL-4/IL-13 biologic franchise for moderate-to-severe atopic dermatitis
- Pfizer
Topical PDE4 therapy for mild-to-moderate atopic dermatitis
- Eli Lilly
IL-13 biologic for moderate-to-severe atopic dermatitis
- Bausch Health
Topical antifungal for toenail onychomycosis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Turn Therapeutics | $9.82 | −0.05% | $288.1M | — | — | — | — |
| Incyte | $128.82 | +3.05% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Arcutis Biotherapeutics | $24.04 | +0.81% | $2.98B | 114.4 | 30.4 | 6.4 | +59.3% |
| Organon | $13.76 | −0.15% | $3.62B | 17.9 | 3.9 | 0.6 | −2.3% |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Pfizer | $28.98 | −0.17% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Bausch Health | $6.82 | −0.07% | $2.55B | — | 1.5 | 0.2 | +11.2% |
| Median | 38.6 | 19.4 | 2.6 | +11.2% |